nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—LIPF—pituitary gland—hypothyroidism	0.0277	0.0495	CbGeAlD
Orlistat—LIPF—testis—hypothyroidism	0.0205	0.0365	CbGeAlD
Orlistat—Menstruation irregular—Levothyroxine—hypothyroidism	0.0167	0.0532	CcSEcCtD
Orlistat—Menstruation irregular—Dextrothyroxine—hypothyroidism	0.0167	0.0532	CcSEcCtD
Orlistat—DAGLB—heart—hypothyroidism	0.0166	0.0296	CbGeAlD
Orlistat—DAGLA—blood—hypothyroidism	0.0159	0.0285	CbGeAlD
Orlistat—DAGLA—testis—hypothyroidism	0.0132	0.0235	CbGeAlD
Orlistat—ABHD16A—adrenal cortex—hypothyroidism	0.013	0.0232	CbGeAlD
Orlistat—PLA2G7—cardiovascular system—hypothyroidism	0.0126	0.0225	CbGeAlD
Orlistat—PLA2G7—Synthesis, secretion, and deacylation of Ghrelin—IGF1—hypothyroidism	0.0126	0.1	CbGpPWpGaD
Orlistat—DAGLB—adrenal gland—hypothyroidism	0.0124	0.0221	CbGeAlD
Orlistat—Menstruation irregular—Liotrix—hypothyroidism	0.0123	0.0391	CcSEcCtD
Orlistat—DAGLA—cerebellum—hypothyroidism	0.0122	0.0217	CbGeAlD
Orlistat—ABHD12—adrenal cortex—hypothyroidism	0.0122	0.0217	CbGeAlD
Orlistat—DAGLB—thyroid gland—hypothyroidism	0.0119	0.0213	CbGeAlD
Orlistat—ABHD12—heart—hypothyroidism	0.0118	0.021	CbGeAlD
Orlistat—PNLIP—heart—hypothyroidism	0.0118	0.021	CbGeAlD
Orlistat—DAGLB—female gonad—hypothyroidism	0.0115	0.0206	CbGeAlD
Orlistat—PLA2G7—pituitary gland—hypothyroidism	0.0112	0.02	CbGeAlD
Orlistat—PNLIP—cardiovascular system—hypothyroidism	0.0111	0.0198	CbGeAlD
Orlistat—ABHD16A—pituitary gland—hypothyroidism	0.0105	0.0187	CbGeAlD
Orlistat—DAGLB—testis—hypothyroidism	0.0102	0.0183	CbGeAlD
Orlistat—PLA2G7—adrenal gland—hypothyroidism	0.00999	0.0178	CbGeAlD
Orlistat—PLA2G7—blood—hypothyroidism	0.00999	0.0178	CbGeAlD
Orlistat—FASN—heart—hypothyroidism	0.00988	0.0176	CbGeAlD
Orlistat—PNLIP—pituitary gland—hypothyroidism	0.00983	0.0176	CbGeAlD
Orlistat—ABHD12—pituitary gland—hypothyroidism	0.00983	0.0176	CbGeAlD
Orlistat—DAGLB—liver—hypothyroidism	0.00967	0.0173	CbGeAlD
Orlistat—PLA2G7—thyroid gland—hypothyroidism	0.00964	0.0172	CbGeAlD
Orlistat—DAGLB—cerebellum—hypothyroidism	0.00945	0.0169	CbGeAlD
Orlistat—ABHD16A—blood—hypothyroidism	0.00937	0.0167	CbGeAlD
Orlistat—PLA2G7—female gonad—hypothyroidism	0.00931	0.0166	CbGeAlD
Orlistat—PLA2G7—Peptide hormone metabolism—TSHB—hypothyroidism	0.00921	0.0733	CbGpPWpGaD
Orlistat—ABHD16A—thyroid gland—hypothyroidism	0.00905	0.0161	CbGeAlD
Orlistat—ABHD12—adrenal gland—hypothyroidism	0.00878	0.0157	CbGeAlD
Orlistat—ABHD12—blood—hypothyroidism	0.00878	0.0157	CbGeAlD
Orlistat—PNLIP—blood—hypothyroidism	0.00878	0.0157	CbGeAlD
Orlistat—ABHD16A—female gonad—hypothyroidism	0.00874	0.0156	CbGeAlD
Orlistat—ABHD12—thyroid gland—hypothyroidism	0.00848	0.0151	CbGeAlD
Orlistat—FASN—pituitary gland—hypothyroidism	0.00825	0.0147	CbGeAlD
Orlistat—ABHD12—female gonad—hypothyroidism	0.00819	0.0146	CbGeAlD
Orlistat—PNLIP—female gonad—hypothyroidism	0.00819	0.0146	CbGeAlD
Orlistat—PLA2G7—liver—hypothyroidism	0.00781	0.0139	CbGeAlD
Orlistat—ABHD16A—testis—hypothyroidism	0.00775	0.0138	CbGeAlD
Orlistat—FASN—adrenal gland—hypothyroidism	0.00737	0.0132	CbGeAlD
Orlistat—FASN—blood—hypothyroidism	0.00737	0.0132	CbGeAlD
Orlistat—ABHD12—testis—hypothyroidism	0.00726	0.013	CbGeAlD
Orlistat—ABHD16A—cerebellum—hypothyroidism	0.00716	0.0128	CbGeAlD
Orlistat—Increased appetite—Dextrothyroxine—hypothyroidism	0.00714	0.0227	CcSEcCtD
Orlistat—Increased appetite—Levothyroxine—hypothyroidism	0.00714	0.0227	CcSEcCtD
Orlistat—FASN—thyroid gland—hypothyroidism	0.00711	0.0127	CbGeAlD
Orlistat—Hypoglycaemia—Levothyroxine—hypothyroidism	0.00688	0.0219	CcSEcCtD
Orlistat—Hypoglycaemia—Dextrothyroxine—hypothyroidism	0.00688	0.0219	CcSEcCtD
Orlistat—FASN—female gonad—hypothyroidism	0.00687	0.0123	CbGeAlD
Orlistat—PNLIP—liver—hypothyroidism	0.00687	0.0123	CbGeAlD
Orlistat—ABHD12—liver—hypothyroidism	0.00687	0.0123	CbGeAlD
Orlistat—ABHD12—cerebellum—hypothyroidism	0.00671	0.012	CbGeAlD
Orlistat—CYP3A4—urine—hypothyroidism	0.00611	0.0109	CbGeAlD
Orlistat—FASN—testis—hypothyroidism	0.0061	0.0109	CbGeAlD
Orlistat—FASN—liver—hypothyroidism	0.00576	0.0103	CbGeAlD
Orlistat—Sweating increased—Levothyroxine—hypothyroidism	0.00565	0.018	CcSEcCtD
Orlistat—Sweating increased—Dextrothyroxine—hypothyroidism	0.00565	0.018	CcSEcCtD
Orlistat—FASN—cerebellum—hypothyroidism	0.00563	0.0101	CbGeAlD
Orlistat—Body temperature increased—Liothyronine—hypothyroidism	0.00531	0.0169	CcSEcCtD
Orlistat—Increased appetite—Liotrix—hypothyroidism	0.00526	0.0167	CcSEcCtD
Orlistat—Hypoglycaemia—Liotrix—hypothyroidism	0.00506	0.0161	CcSEcCtD
Orlistat—PLA2G4A—adrenal cortex—hypothyroidism	0.00491	0.00876	CbGeAlD
Orlistat—PLA2G4A—heart—hypothyroidism	0.00475	0.00847	CbGeAlD
Orlistat—Hypokalaemia—Liotrix—hypothyroidism	0.00449	0.0143	CcSEcCtD
Orlistat—PLA2G4A—cardiovascular system—hypothyroidism	0.00448	0.008	CbGeAlD
Orlistat—Abdominal distension—Liotrix—hypothyroidism	0.0043	0.0137	CcSEcCtD
Orlistat—Bronchospasm—Liotrix—hypothyroidism	0.0042	0.0134	CcSEcCtD
Orlistat—DAGLA—G alpha (q) signalling events—TRH—hypothyroidism	0.00417	0.0332	CbGpPWpGaD
Orlistat—DAGLB—G alpha (q) signalling events—TRH—hypothyroidism	0.00417	0.0332	CbGpPWpGaD
Orlistat—Sweating increased—Liotrix—hypothyroidism	0.00416	0.0132	CcSEcCtD
Orlistat—Alopecia—Dextrothyroxine—hypothyroidism	0.0041	0.0131	CcSEcCtD
Orlistat—Alopecia—Levothyroxine—hypothyroidism	0.0041	0.0131	CcSEcCtD
Orlistat—PLA2G4A—pituitary gland—hypothyroidism	0.00397	0.00708	CbGeAlD
Orlistat—Renal failure—Liotrix—hypothyroidism	0.00374	0.0119	CcSEcCtD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.00373	0.0297	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.00373	0.0297	CbGpPWpGaD
Orlistat—Angioedema—Dextrothyroxine—hypothyroidism	0.00369	0.0118	CcSEcCtD
Orlistat—Angioedema—Levothyroxine—hypothyroidism	0.00369	0.0118	CcSEcCtD
Orlistat—PLA2G7—Peptide hormone metabolism—POMC—hypothyroidism	0.00361	0.0287	CbGpPWpGaD
Orlistat—Palpitations—Levothyroxine—hypothyroidism	0.00357	0.0114	CcSEcCtD
Orlistat—Palpitations—Dextrothyroxine—hypothyroidism	0.00357	0.0114	CcSEcCtD
Orlistat—PLA2G4A—adrenal gland—hypothyroidism	0.00354	0.00633	CbGeAlD
Orlistat—PLA2G4A—blood—hypothyroidism	0.00354	0.00632	CbGeAlD
Orlistat—Convulsion—Levothyroxine—hypothyroidism	0.0035	0.0112	CcSEcCtD
Orlistat—Convulsion—Dextrothyroxine—hypothyroidism	0.0035	0.0112	CcSEcCtD
Orlistat—PLA2G7—Peptide hormone metabolism—IGF1—hypothyroidism	0.00347	0.0276	CbGpPWpGaD
Orlistat—Anxiety—Dextrothyroxine—hypothyroidism	0.00343	0.0109	CcSEcCtD
Orlistat—Anxiety—Levothyroxine—hypothyroidism	0.00343	0.0109	CcSEcCtD
Orlistat—PLA2G4A—thyroid gland—hypothyroidism	0.00342	0.0061	CbGeAlD
Orlistat—PLA2G4A—female gonad—hypothyroidism	0.0033	0.0059	CbGeAlD
Orlistat—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00319	0.0102	CcSEcCtD
Orlistat—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00319	0.0102	CcSEcCtD
Orlistat—Alopecia—Liotrix—hypothyroidism	0.00302	0.00961	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.00301	0.00957	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.00301	0.00957	CcSEcCtD
Orlistat—Insomnia—Dextrothyroxine—hypothyroidism	0.00298	0.0095	CcSEcCtD
Orlistat—Insomnia—Levothyroxine—hypothyroidism	0.00298	0.0095	CcSEcCtD
Orlistat—PLA2G4A—testis—hypothyroidism	0.00293	0.00523	CbGeAlD
Orlistat—Flatulence—Liotrix—hypothyroidism	0.00293	0.00933	CcSEcCtD
Orlistat—Dysgeusia—Liotrix—hypothyroidism	0.00291	0.00927	CcSEcCtD
Orlistat—Fatigue—Dextrothyroxine—hypothyroidism	0.00284	0.00906	CcSEcCtD
Orlistat—Fatigue—Levothyroxine—hypothyroidism	0.00284	0.00906	CcSEcCtD
Orlistat—Vision blurred—Liotrix—hypothyroidism	0.0028	0.00892	CcSEcCtD
Orlistat—Feeling abnormal—Levothyroxine—hypothyroidism	0.00272	0.00866	CcSEcCtD
Orlistat—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00272	0.00866	CcSEcCtD
Orlistat—Angioedema—Liotrix—hypothyroidism	0.00272	0.00865	CcSEcCtD
Orlistat—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.0027	0.00859	CcSEcCtD
Orlistat—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.0027	0.00859	CcSEcCtD
Orlistat—PLA2G4A—Prostaglandin Synthesis and Regulation—PRL—hypothyroidism	0.00267	0.0213	CbGpPWpGaD
Orlistat—Palpitations—Liotrix—hypothyroidism	0.00263	0.00837	CcSEcCtD
Orlistat—Urticaria—Dextrothyroxine—hypothyroidism	0.00262	0.00835	CcSEcCtD
Orlistat—Urticaria—Levothyroxine—hypothyroidism	0.00262	0.00835	CcSEcCtD
Orlistat—Body temperature increased—Levothyroxine—hypothyroidism	0.00261	0.0083	CcSEcCtD
Orlistat—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00261	0.0083	CcSEcCtD
Orlistat—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00261	0.0083	CcSEcCtD
Orlistat—Abdominal pain—Levothyroxine—hypothyroidism	0.00261	0.0083	CcSEcCtD
Orlistat—Convulsion—Liotrix—hypothyroidism	0.00258	0.0082	CcSEcCtD
Orlistat—Chest pain—Liotrix—hypothyroidism	0.00253	0.00806	CcSEcCtD
Orlistat—Anxiety—Liotrix—hypothyroidism	0.00252	0.00803	CcSEcCtD
Orlistat—Oedema—Liotrix—hypothyroidism	0.00243	0.00773	CcSEcCtD
Orlistat—Anaphylactic shock—Liotrix—hypothyroidism	0.00243	0.00773	CcSEcCtD
Orlistat—Infection—Liotrix—hypothyroidism	0.00241	0.00768	CcSEcCtD
Orlistat—Asthenia—Dextrothyroxine—hypothyroidism	0.00237	0.00754	CcSEcCtD
Orlistat—Asthenia—Levothyroxine—hypothyroidism	0.00237	0.00754	CcSEcCtD
Orlistat—Hyperhidrosis—Liotrix—hypothyroidism	0.00235	0.00747	CcSEcCtD
Orlistat—Pruritus—Dextrothyroxine—hypothyroidism	0.00233	0.00743	CcSEcCtD
Orlistat—Pruritus—Levothyroxine—hypothyroidism	0.00233	0.00743	CcSEcCtD
Orlistat—Diarrhoea—Levothyroxine—hypothyroidism	0.00226	0.00719	CcSEcCtD
Orlistat—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00226	0.00719	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.00221	0.00704	CcSEcCtD
Orlistat—Insomnia—Liotrix—hypothyroidism	0.0022	0.00699	CcSEcCtD
Orlistat—DAGLA—G alpha (q) signalling events—AVP—hypothyroidism	0.00219	0.0174	CbGpPWpGaD
Orlistat—DAGLB—G alpha (q) signalling events—AVP—hypothyroidism	0.00219	0.0174	CbGpPWpGaD
Orlistat—Paraesthesia—Liotrix—hypothyroidism	0.00218	0.00694	CcSEcCtD
Orlistat—Decreased appetite—Liotrix—hypothyroidism	0.00211	0.00672	CcSEcCtD
Orlistat—Vomiting—Dextrothyroxine—hypothyroidism	0.0021	0.00668	CcSEcCtD
Orlistat—Vomiting—Levothyroxine—hypothyroidism	0.0021	0.00668	CcSEcCtD
Orlistat—Fatigue—Liotrix—hypothyroidism	0.00209	0.00666	CcSEcCtD
Orlistat—Rash—Levothyroxine—hypothyroidism	0.00208	0.00662	CcSEcCtD
Orlistat—Rash—Dextrothyroxine—hypothyroidism	0.00208	0.00662	CcSEcCtD
Orlistat—Dermatitis—Dextrothyroxine—hypothyroidism	0.00208	0.00662	CcSEcCtD
Orlistat—Dermatitis—Levothyroxine—hypothyroidism	0.00208	0.00662	CcSEcCtD
Orlistat—Headache—Dextrothyroxine—hypothyroidism	0.00207	0.00658	CcSEcCtD
Orlistat—Headache—Levothyroxine—hypothyroidism	0.00207	0.00658	CcSEcCtD
Orlistat—Feeling abnormal—Liotrix—hypothyroidism	0.002	0.00637	CcSEcCtD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	0.00199	0.0158	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	0.00199	0.0158	CbGpPWpGaD
Orlistat—Gastrointestinal pain—Liotrix—hypothyroidism	0.00198	0.00632	CcSEcCtD
Orlistat—Nausea—Dextrothyroxine—hypothyroidism	0.00196	0.00624	CcSEcCtD
Orlistat—Nausea—Levothyroxine—hypothyroidism	0.00196	0.00624	CcSEcCtD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.00196	0.0156	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.00196	0.0156	CbGpPWpGaD
Orlistat—Urticaria—Liotrix—hypothyroidism	0.00193	0.00614	CcSEcCtD
Orlistat—Body temperature increased—Liotrix—hypothyroidism	0.00192	0.00611	CcSEcCtD
Orlistat—Abdominal pain—Liotrix—hypothyroidism	0.00192	0.00611	CcSEcCtD
Orlistat—Hypersensitivity—Liotrix—hypothyroidism	0.00179	0.00569	CcSEcCtD
Orlistat—Asthenia—Liotrix—hypothyroidism	0.00174	0.00554	CcSEcCtD
Orlistat—PLA2G7—Metabolism of proteins—TSHB—hypothyroidism	0.00174	0.0138	CbGpPWpGaD
Orlistat—Pruritus—Liotrix—hypothyroidism	0.00172	0.00547	CcSEcCtD
Orlistat—Diarrhoea—Liotrix—hypothyroidism	0.00166	0.00529	CcSEcCtD
Orlistat—Dizziness—Liotrix—hypothyroidism	0.0016	0.00511	CcSEcCtD
Orlistat—Vomiting—Liotrix—hypothyroidism	0.00154	0.00491	CcSEcCtD
Orlistat—Rash—Liotrix—hypothyroidism	0.00153	0.00487	CcSEcCtD
Orlistat—Dermatitis—Liotrix—hypothyroidism	0.00153	0.00487	CcSEcCtD
Orlistat—PNLIP—Metabolism—IYD—hypothyroidism	0.00152	0.0121	CbGpPWpGaD
Orlistat—Headache—Liotrix—hypothyroidism	0.00152	0.00484	CcSEcCtD
Orlistat—DAGLB—Hemostasis—SH2B3—hypothyroidism	0.00149	0.0119	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—SH2B3—hypothyroidism	0.00149	0.0119	CbGpPWpGaD
Orlistat—Nausea—Liotrix—hypothyroidism	0.00144	0.00459	CcSEcCtD
Orlistat—PNLIP—Metabolism—ATP5O—hypothyroidism	0.00129	0.0103	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	0.00122	0.00974	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	0.00122	0.00974	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—TPO—hypothyroidism	0.00122	0.00967	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—TRH—hypothyroidism	0.00119	0.00945	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—TRH—hypothyroidism	0.00119	0.00945	CbGpPWpGaD
Orlistat—CYP3A4—blood—hypothyroidism	0.00117	0.00209	CbGeAlD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.00113	0.00896	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—TRH—hypothyroidism	0.00108	0.00858	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—TRH—hypothyroidism	0.00108	0.00858	CbGpPWpGaD
Orlistat—FASN—Metabolism—IYD—hypothyroidism	0.00108	0.00856	CbGpPWpGaD
Orlistat—PLA2G4A—Phospholipid metabolism—PIK3C2A—hypothyroidism	0.00106	0.00845	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—TSHB—hypothyroidism	0.00106	0.00842	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—TSHB—hypothyroidism	0.00106	0.00842	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—TSHR—hypothyroidism	0.00106	0.00842	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—TSHR—hypothyroidism	0.00106	0.00842	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—VAV3—hypothyroidism	0.00103	0.00815	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—VAV3—hypothyroidism	0.00103	0.00815	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—TSHB—hypothyroidism	0.000962	0.00765	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—TSHB—hypothyroidism	0.000962	0.00765	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—TSHR—hypothyroidism	0.000962	0.00765	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—TSHR—hypothyroidism	0.000962	0.00765	CbGpPWpGaD
Orlistat—FASN—Metabolism—ATP5O—hypothyroidism	0.000915	0.00728	CbGpPWpGaD
Orlistat—CYP3A4—liver—hypothyroidism	0.000914	0.00163	CbGeAlD
Orlistat—FASN—Metabolism—TPO—hypothyroidism	0.000861	0.00684	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000797	0.00634	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CLTC—hypothyroidism	0.000738	0.00587	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CLTC—hypothyroidism	0.000738	0.00587	CbGpPWpGaD
Orlistat—PLA2G4A—Opioid Signalling—POMC—hypothyroidism	0.000715	0.00569	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—POMC—hypothyroidism	0.000681	0.00542	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—IGF1—hypothyroidism	0.000655	0.00521	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—VAV3—hypothyroidism	0.000648	0.00515	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—VAV3—hypothyroidism	0.000648	0.00515	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TRH—hypothyroidism	0.000638	0.00507	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TRH—hypothyroidism	0.000638	0.00507	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—IGF1—hypothyroidism	0.000631	0.00502	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—IGF1—hypothyroidism	0.000631	0.00502	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AVP—hypothyroidism	0.000624	0.00497	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AVP—hypothyroidism	0.000624	0.00497	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CLTC—hypothyroidism	0.000611	0.00486	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—VAV3—hypothyroidism	0.000588	0.00468	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—VAV3—hypothyroidism	0.000588	0.00468	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TSHB—hypothyroidism	0.000568	0.00452	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TSHR—hypothyroidism	0.000568	0.00452	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TSHB—hypothyroidism	0.000568	0.00452	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TSHR—hypothyroidism	0.000568	0.00452	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AVP—hypothyroidism	0.000567	0.00451	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AVP—hypothyroidism	0.000567	0.00451	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—TSHB—hypothyroidism	0.000563	0.00448	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TRH—hypothyroidism	0.000528	0.0042	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SH2B3—hypothyroidism	0.000506	0.00403	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SH2B3—hypothyroidism	0.000506	0.00403	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3C2A—hypothyroidism	0.000502	0.00399	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	0.0005	0.00398	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	0.000495	0.00394	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TSHB—hypothyroidism	0.000471	0.00374	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TSHR—hypothyroidism	0.000471	0.00374	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—IYD—hypothyroidism	0.000462	0.00367	CbGpPWpGaD
Orlistat—PNLIP—Disease—PRL—hypothyroidism	0.000445	0.00354	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—SLC5A5—hypothyroidism	0.000422	0.00335	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SH2B3—hypothyroidism	0.00042	0.00334	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—POMC—hypothyroidism	0.000415	0.0033	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—POMC—hypothyroidism	0.000415	0.0033	CbGpPWpGaD
Orlistat—FASN—Metabolism—TSHB—hypothyroidism	0.000398	0.00317	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—ATP5O—hypothyroidism	0.000393	0.00312	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—POMC—hypothyroidism	0.000377	0.003	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—POMC—hypothyroidism	0.000377	0.003	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SH2B3—hypothyroidism	0.000376	0.00299	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PRL—hypothyroidism	0.000376	0.00299	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PRL—hypothyroidism	0.000376	0.00299	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TPO—hypothyroidism	0.000369	0.00294	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3C2A—hypothyroidism	0.000355	0.00282	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	0.00035	0.00279	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VAV3—hypothyroidism	0.000348	0.00276	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VAV3—hypothyroidism	0.000348	0.00276	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	0.000346	0.00275	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000342	0.00272	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AVP—hypothyroidism	0.000335	0.00266	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AVP—hypothyroidism	0.000335	0.00266	CbGpPWpGaD
Orlistat—FASN—Disease—PRL—hypothyroidism	0.000315	0.0025	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PRL—hypothyroidism	0.000311	0.00248	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	0.000308	0.00245	CbGpPWpGaD
Orlistat—FASN—Metabolism—SLC5A5—hypothyroidism	0.000298	0.00237	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VAV3—hypothyroidism	0.000288	0.00229	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AVP—hypothyroidism	0.000277	0.00221	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—TRH—hypothyroidism	0.000272	0.00216	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VAV3—hypothyroidism	0.000258	0.00205	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—TSHB—hypothyroidism	0.000242	0.00192	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—TSHR—hypothyroidism	0.000242	0.00192	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—POMC—hypothyroidism	0.000223	0.00177	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—POMC—hypothyroidism	0.000223	0.00177	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—POMC—hypothyroidism	0.000221	0.00175	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IGF1—hypothyroidism	0.000214	0.0017	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IGF1—hypothyroidism	0.000214	0.0017	CbGpPWpGaD
Orlistat—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000213	0.00169	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CLTC—hypothyroidism	0.000186	0.00148	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—POMC—hypothyroidism	0.000184	0.00147	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IGF1—hypothyroidism	0.000177	0.00141	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000173	0.00137	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—TSHB—hypothyroidism	0.000171	0.00136	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TRH—hypothyroidism	0.00016	0.00128	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IGF1—hypothyroidism	0.000159	0.00126	CbGpPWpGaD
Orlistat—FASN—Metabolism—POMC—hypothyroidism	0.000156	0.00124	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3C2A—hypothyroidism	0.000152	0.00121	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	0.00015	0.0012	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—VAV3—hypothyroidism	0.000148	0.00118	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TSHB—hypothyroidism	0.000143	0.00114	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TSHR—hypothyroidism	0.000143	0.00114	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AVP—hypothyroidism	0.000143	0.00113	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC5A5—hypothyroidism	0.000128	0.00102	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SH2B3—hypothyroidism	0.000127	0.00101	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—IYD—hypothyroidism	0.000108	0.00086	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—POMC—hypothyroidism	9.48e-05	0.000754	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PRL—hypothyroidism	9.45e-05	0.000752	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ATP5O—hypothyroidism	9.2e-05	0.000732	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—POMC—hypothyroidism	9.17e-05	0.000729	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VAV3—hypothyroidism	8.74e-05	0.000696	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TPO—hypothyroidism	8.65e-05	0.000688	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AVP—hypothyroidism	8.43e-05	0.00067	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—POMC—hypothyroidism	6.7e-05	0.000533	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—POMC—hypothyroidism	5.6e-05	0.000445	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IGF1—hypothyroidism	5.39e-05	0.000428	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—TSHB—hypothyroidism	4e-05	0.000318	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	3.57e-05	0.000284	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC5A5—hypothyroidism	3e-05	0.000238	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—POMC—hypothyroidism	1.57e-05	0.000125	CbGpPWpGaD
